Morphic Holding Inc

MORF

NASDAQ. Currency in USD

27.69 +0.17 ( +0.62% )

Real time prices: December 01

Market Cap.
1.07B
Beta (5Y monthly)
1.26
Price/Earnings
-
EPS (TTM)
-1.52
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
184,517
1y Target Est.
63.38
Day's Range
26.79
-
27.90
52 Week's Range
19.23
-
52.34

Historical Summary

Performance
EPS growth
Share Buybacks

About Morphic Holding Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.morphictx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
36.96M
Employees
103
Address
35 Gatehouse Drive, A2, Waltham, MA, United States, 02451
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Latest news

Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company...
By GlobeNewswire Inc. - 3 weeks ago

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue...
By Zacks Investment Research - 4 weeks ago

BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
By Zacks Investment Research - 5 weeks ago

Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Saturating receptor occupancy at 100 and 200 mg BID doses
By GlobeNewswire Inc. - 5 weeks ago

Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management...
By Zacks Investment Research - 5 weeks ago

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow...
By GlobeNewswire Inc. - 5 weeks ago

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab
Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants,...
By Zacks Investment Research - 6 weeks ago

Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension
Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This...
By Zacks Investment Research - 6 weeks ago